Literature DB >> 31704340

The skeletal phenotype of intermediate GM1 gangliosidosis: Clinical, radiographic and densitometric features, and implications for clinical monitoring and intervention.

Carlos R Ferreira1, Debra S Regier2, Robin Yoon3, Kristen S Pan4, Jean M Johnston5, Sandra Yang5, Jürgen W Spranger6, Cynthia J Tifft7.   

Abstract

GM1 gangliosidosis is a lysosomal storage disorder caused by mutations in GLB1 encoding a lysosomal β-galactosidase. This disease is a continuum from the severe infantile form with rapid neurological decline to the chronic adult form, which is not life-limiting. The intermediate or type 2 form can be further classified into late infantile and juvenile forms. The frequency and severity of skeletal outcomes in late infantile and juvenile patients have not been characterized. Our goals are to describe the radiological skeletal abnormalities, bone mineral density (BMD), and frequency of fractures in patients with intermediate GM1 gangliosidosis. We evaluated 13 late infantile and 21 juvenile patients as part of an ongoing natural history study. Average time from onset of symptoms to diagnosis was 1.9 and 6.3 years for late infantile and juvenile patients, respectively. All late infantile patients had odontoid hypoplasia and pear-shaped vertebral bodies, the frequency of which was significantly different than in patients with juvenile disease (none and 14%, respectively). Juvenile patients had irregular endplates of the vertebral bodies (15/21), central indentation of endplates (10/21), and squared and flat vertebral bodies (10/21); all allowed radiographic differentiation from late infantile patients. Lumbar spine, femoral neck, and total hip BMD were significantly decreased (-2.1, -2.2, and -1.8 Z-scores respectively). Lumbar spine BMD peaked at 19 years, while distal forearm BMD peaked at 30 years. Despite low BMD, no patients exhibited fractures. We have demonstrated that all late infantile patients have some degree of odontoid hypoplasia suggesting the need for cervical spine evaluation particularly prior to anesthesia, whereas juvenile patients had variable skeletal involvement often affecting activities of daily living. Type 2 GM1 gangliosidosis patients have skeletal abnormalities that are both an early indication of their diagnosis, and require monitoring and management to ensure the highest possible quality of life. Published by Elsevier Inc.

Entities:  

Keywords:  Beta-galactosidase deficiency; GM1 gangliosidosis type 2; Lysosomal storage disease; Skeletal dysplasia

Mesh:

Year:  2019        PMID: 31704340      PMCID: PMC6937522          DOI: 10.1016/j.bone.2019.115142

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Tay-Sachs' disease with visceral involvement and its relationship to Niemann-Pick's disease.

Authors:  R M NORMAN; H URICH; A H TINGEY; R A GOODBODY
Journal:  J Pathol Bacteriol       Date:  1959-10

2.  Hyperphosphatasemia in GM1 gangliosidosis.

Authors:  R Denis; J L Wayemberg; M Vermeulen; F Gorus; I Liebaers; E Vamos
Journal:  J Pediatr       Date:  1992-01       Impact factor: 4.406

3.  New GLB1 mutation in siblings with Morquio type B disease presenting with mental regression.

Authors:  Fabiana Quoos Mayer; Fernanda dos Santos Pereira; Anthony H Fensom; Christina Slade; Ursula Matte; Roberto Giugliani
Journal:  Mol Genet Metab       Date:  2008-12-16       Impact factor: 4.797

4.  Gangliosidosis (GM1). A re-evaluation of the vertebral deformity.

Authors:  J G Rabinowitz; M Sacher
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1974-05

5.  Progressive mental regression in siblings with Morquio disease type B (mucopolysaccharidosis IV B).

Authors:  R Giugliani; M Jackson; S J Skinner; C M Vimal; A H Fensom; N Fahmy; A Sjövall; P F Benson
Journal:  Clin Genet       Date:  1987-11       Impact factor: 4.438

6.  Morquio B syndrome: a primary defect in beta-galactosidase.

Authors:  G T van der Horst; W J Kleijer; A T Hoogeveen; J G Huijmans; W Blom; O P van Diggelen
Journal:  Am J Med Genet       Date:  1983-10

7.  Radiographic skeletal changes in juvenile GM1-gangliosidosis.

Authors:  T Owman; S Sjöblad; J Göthlin
Journal:  Rofo       Date:  1980-06

8.  Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.

Authors:  Toshika Okumiya; Hitoshi Sakuraba; Ryoichi Kase; Tetsuro Sugiura
Journal:  Mol Genet Metab       Date:  2003-01       Impact factor: 4.797

9.  Human beta-galactosidase gene mutations in morquio B disease.

Authors:  A Oshima; K Yoshida; M Shimmoto; Y Fukuhara; H Sakuraba; Y Suzuki
Journal:  Am J Hum Genet       Date:  1991-11       Impact factor: 11.025

10.  Morquio B patient/caregiver survey: First insight into the natural course of a rare GLB1 related condition.

Authors:  Maria Bleier; Nataliya Yuskiv; Tina Priest; Marioara Angela Moisa Popurs; Sylvia Stockler-Ipsiroglu
Journal:  Mol Genet Metab Rep       Date:  2018-07-20
View more
  4 in total

1.  A GM1 gangliosidosis mutant mouse model exhibits activated microglia and disturbed autophagy.

Authors:  Sichi Liu; Yuyu Feng; Yonglan Huang; Xiaoling Jiang; Chengfang Tang; Fang Tang; Chunhua Zeng; Li Liu
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-14

2.  Late-infantile GM1 gangliosidosis: A case report.

Authors:  Eu Seon Noh; Hye Mi Park; Min Sun Kim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

Review 3.  GM1 Gangliosidosis-A Mini-Review.

Authors:  Elena-Raluca Nicoli; Ida Annunziata; Alessandra d'Azzo; Frances M Platt; Cynthia J Tifft; Karolina M Stepien
Journal:  Front Genet       Date:  2021-09-03       Impact factor: 4.599

4.  The juvenile gangliosidoses: A timeline of clinical change.

Authors:  Kelly E King; Sarah Kim; Chester B Whitley; Jeanine R Jarnes-Utz
Journal:  Mol Genet Metab Rep       Date:  2020-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.